ZUO LI YAO YE(SZ:300181) 智通财经网·2025-12-14 15:26Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of RMB 356 million, which will enhance the company's product structure and expand its treatment areas, particularly focusing on women's, children's, and elderly health management [1][2]. Group 1 - The acquisition includes the research and production technical data, marketing licenses, trademarks, patents, and employee labor relations related to the already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)" [1]. - The acquisition is aligned with the national health development strategy, aiming to establish a comprehensive health product and service chain covering all age groups from children to the elderly [1]. - The asset group has demonstrated strong profitability, with a net profit of RMB 45.79 million achieved from January to September 2025, indicating good earning potential [2].